Timothy Nicholas

825 total citations
47 papers, 557 citations indexed

About

Timothy Nicholas is a scholar working on Molecular Biology, Pharmacology and Physiology. According to data from OpenAlex, Timothy Nicholas has authored 47 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Pharmacology and 9 papers in Physiology. Recurrent topics in Timothy Nicholas's work include Cholinesterase and Neurodegenerative Diseases (9 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Alzheimer's disease research and treatments (5 papers). Timothy Nicholas is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (9 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Alzheimer's disease research and treatments (5 papers). Timothy Nicholas collaborates with scholars based in United States, United Kingdom and Russia. Timothy Nicholas's co-authors include Brian Corrigan, Holly Soares, Kaori Ito, Elias Schwam, Clare B. Billing, Richard Anziano, Jonathan French, Qinying Zhao, Terence Fullerton and Elyse Katz and has published in prestigious journals such as PLoS ONE, Annals of the Rheumatic Diseases and Journal of Investigative Dermatology.

In The Last Decade

Timothy Nicholas

45 papers receiving 545 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Timothy Nicholas United States	13	145	144	108	105	59	47	557
Pallav Bhatnagar United States	14	114 0.8×	207 1.4×	233 2.2×	115 1.1×	63 1.1×	28	1.2k
Angelica Quartino United States	17	390 2.7×	221 1.5×	203 1.9×	99 0.9×	18 0.3×	48	988
Leslie Williams United States	10	166 1.1×	49 0.3×	93 0.9×	39 0.4×	74 1.3×	17	424
Sebastian Ueckert Sweden	11	44 0.3×	65 0.5×	35 0.3×	57 0.5×	14 0.2×	34	461
Eugène Cox United States	12	51 0.4×	154 1.1×	43 0.4×	93 0.9×	38 0.6×	22	623
Jessica Mancuso United States	12	132 0.9×	140 1.0×	97 0.9×	60 0.6×	18 0.3×	28	552
Rajeev Ayyagari United States	16	42 0.3×	94 0.7×	24 0.2×	168 1.6×	86 1.5×	82	1.0k
Vincent Yip United Kingdom	14	110 0.8×	95 0.7×	228 2.1×	73 0.7×	24 0.4×	28	697
Megan Kane United States	11	46 0.3×	259 1.8×	68 0.6×	64 0.6×	49 0.8×	28	660

Countries citing papers authored by Timothy Nicholas

Since Specialization

Citations

This map shows the geographic impact of Timothy Nicholas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Nicholas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Nicholas more than expected).

Fields of papers citing papers by Timothy Nicholas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Nicholas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Nicholas. The network helps show where Timothy Nicholas may publish in the future.

Co-authorship network of co-authors of Timothy Nicholas

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Nicholas. A scholar is included among the top collaborators of Timothy Nicholas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Nicholas. Timothy Nicholas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sahasrabudhe, Vaishali, Timothy Nicholas, Gianluca Nucci, Cynthia J. Musante, & Brian Corrigan. (2025). Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost. Clinical Pharmacology & Therapeutics. 118(2). 378–385. 7 indexed citations

Chang, Cheng, et al.. (2024). Pharmacokinetic Profile of Brepocitinib with Topical Administration in Atopic Dermatitis and Psoriasis Populations: Strategy to Inform Clinical Trial Design in Adult and Pediatric Populations. Pharmaceutical Research. 41(4). 623–636.

Tsamandouras, Nikolaos, et al.. (2024). Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis. Journal of Pharmacokinetics and Pharmacodynamics. 51(3). 265–277. 2 indexed citations

Chang, Cheng, et al.. (2024). Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis. CPT Pharmacometrics & Systems Pharmacology. 13(4). 599–611. 3 indexed citations

Wang, X., Jillian G. Johnson, Linda S. Wood, et al.. (2024). Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure. Clinical Pharmacology in Drug Development. 13(10). 1098–1107. 1 indexed citations

Purohit, Vivek S., et al.. (2023). Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development. Clinical Pharmacokinetics. 62(12). 1765–1779. 11 indexed citations

Liu, Jiang, et al.. (2023). Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development. CPT Pharmacometrics & Systems Pharmacology. 13(5). 691–709. 23 indexed citations

Chan, Phylinda L. S., Ravi Shankar Prasad Singh, Donna S. Cox, et al.. (2023). Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis. CPT Pharmacometrics & Systems Pharmacology. 12(12). 1897–1910. 5 indexed citations

Riley, Steve, et al.. (2021). Population pharmacokinetic modelling and simulation of tafamidis in healthy subjects and patients with transthyretin amyloidosis. British Journal of Clinical Pharmacology. 87(9). 3574–3587. 1 indexed citations

10.

Purohit, Vivek S., J.L. Werth, D. Graham, & Timothy Nicholas. (2020). 512 Patient and disease characteristic predictors of systemic exposure to crisaborole. Journal of Investigative Dermatology. 140(7). S70–S70. 1 indexed citations

11.

Romero, Klaus, Daniela J. Conrado, Jackson Burton, et al.. (2019). Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease. Clinical and Translational Science. 12(3). 240–246. 12 indexed citations

12.

Stepanov, Alexander A., et al.. (2018). A mathematical model of multisite phosphorylation of tau protein. PLoS ONE. 13(2). e0192519–e0192519. 20 indexed citations

13.

Smith, Michael K., Kaori Ito, E. Niclas Jonsson, et al.. (2018). PharmTeX: a LaTeX-Based Open-Source Platform for Automated Reporting Workflow. The AAPS Journal. 20(3). 52–52. 4 indexed citations

14.

Obach, R. Scott, Jian Lin, Emi Kimoto, et al.. (2017). Estimation of Circulating Drug Metabolite Exposure in Human Using In Vitro Data and Physiologically Based Pharmacokinetic Modeling: Example of a High Metabolite/Parent Drug Ratio. Drug Metabolism and Disposition. 46(2). 89–99. 9 indexed citations

15.

Conrado, Daniela J., Timothy Nicholas, Kuenhi Tsai, et al.. (2017). Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis. Clinical and Translational Science. 11(1). 63–70. 35 indexed citations

16.

Demin, Oleg, et al.. (2017). Studying the Progression of Amyloid Pathology and Its Therapy Using Translational Longitudinal Model of Accumulation and Distribution of Amyloid Beta. CPT Pharmacometrics & Systems Pharmacology. 6(10). 676–685. 13 indexed citations

17.

Schwam, Elias, Timothy Nicholas, Robert Chew, et al.. (2014). A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer’s Disease. Current Alzheimer Research. 11(5). 413–421. 64 indexed citations

18.

Rush, David, et al.. (1995). Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study.. PubMed. 41(2). 126–36. 62 indexed citations

19.

Blanchard, Carine, D. Hackett, P. Danjou, & Timothy Nicholas. (1995). P-2-99 A randomized double-blind comparison of venlafaxine, imipramine and placebo in general practice patients with mild moderate depression. European Neuropsychopharmacology. 5(3). 308–308. 2 indexed citations

20.

Ryan, Patrick, et al.. (1987). A double-blind comparison of fenoprofen calcium, acetaminophen, and placebo in the palliative treatment of common nonbacterial upper respiratory infections. Current Therapeutic Research. 41(1). 17–23. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact